Novel Antidiabetic Therapies and Cardiovascular Risk Reduction
| Autor: | Jillian Thompson, Sydney Schacht, Florence Rothenberg |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry Liraglutide Psychological intervention Type 2 Diabetes Mellitus General Medicine Disease 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Diabetes mellitus Empagliflozin Medicine 030212 general & internal medicine Glycated hemoglobin Risk factor Cardiology and Cardiovascular Medicine business Intensive care medicine medicine.drug |
| Zdroj: | Cardiology Clinics. 37:335-343 |
| ISSN: | 0733-8651 |
| DOI: | 10.1016/j.ccl.2019.04.007 |
| Popis: | Diabetes is a major risk factor for cardiovascular disease, yet until now treatments for diabetes had only a modest impact on cardiovascular events. New interventions for patients with type 2 diabetes mellitus (oral empagliflozin and injectable liraglutide) are associated with unprecedented reductions in composite cardiovascular outcomes that seem disproportionate to the impact on glycated hemoglobin. This review examines in detail the recent trials that arrived at these conclusions, limitations of these studies, and how these outcomes may influence patient management in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|